Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 44Fluorouracil 16Cisplatin 15Oxaliplatin 13Capecitabine 11Paclitaxel 10lenvatinib 8Leucovorin 8Irinotecan 6Docetaxel 6trifluridine tipiracil drug combination 3regorafenib 3Saline Solution 3Levoleucovorin 3Gemcitabine 3Bevacizumab 3patritumab deruxtecan 2Trastuzumab 2S 1 (combination) 2Radiotherapy 2Cetuximab 2Carboplatin 2zanidatamab 1vicriviroc 1tremelimumab 1tislelizumab 1tipiracil 1spartalizumab 1sinoporphyrin sodium 1ribociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × sinoporphyrin sodium × Gastrointestinal × Clear all
NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Unknown
54 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡